Siemens Healthineers AG

}

Bernd Montag said the quarter validated the company’s market strength, especially through the 1.27 equipment book-to-bill and the two large U.S. value partnerships with Cleveland Clinic and Vanderbilt Health. He emphasized that Imaging’s softer quarter was temporary, driven by comp pressure and shipment timing, and said Q4 should show a clear acceleration. His tone was confident on the core businesses and innovation pipeline, but candid that Diagnostics is still structurally challenged by China rebasing and legacy platform dilution.

Jochen Schmitz focused on segment-level drivers, noting Imaging margin before tariff refunds of 21.6%, Precision Therapy margin before refunds of 14.1%, and Diagnostics margin ex refunds around 3%. He said earnings were boosted by tariff refunds, which added about EUR 0.15 to EPS, but underlying profitability remained decent at 15.4% excluding the refunds despite FX, inflation and softer growth. He also highlighted cash above EUR 1 billion, cash conversion of 1.12, net debt of around EUR 12 billion, and leverage of 2.8x, and explained that FY26 revenue guidance was cut because Diagnostics is not recovering as expected while EPS guidance rose exactly by the tariff refund benefit.

Analysts pressed management on whether the FY27 EPS bridge was conservative, how much separation cost and branding fee were reflected, and whether inflation, higher interest expense, and China procurement were incorporated. Schmitz described the FY27 view as a prudent baseline around EUR 2.25 for 2026 adjusted EPS before the tariff refund, said the separation-cost assumption is a mid-double-digit million euro recurring cost but excludes branding fees, and added that they do not expect a branding fee in coming years. On China, management said imaging centralized bidding was anticipated and already reflected in planning, while they do not assume a near-term recovery in China and will not base the FY27 guide on one.